, a privately funded company focused on vision-related products, has received a patent for the formulation of its dry eye product known as Bio Tears Oral GelCaps.
BioTears include nutrients that have been suggested in clinical trials to control the inflammatory process associated with dry eye, according to the company.
"This is particularly important to the contact lens wearer," said Ellen Troyer, Biosyntrx's chief research officer and BioTears co-inventor. "The BioTears formulation has also been suggested to improve visual acuity after cataract and refractive surgery, particularly following LASIK or implantation of multi-focal intraocular lens."
Copyright 2024 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
